期刊
CURRENT OPINION IN PHARMACOLOGY
卷 24, 期 -, 页码 113-118出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2015.08.006
关键词
-
资金
- Leukemia and Lymphoma Research UK
- Cancer Research UK
- Medical Research Council
- European Union FP7 ATTACK
- European Union FP7 ATTRACT
- National Institute of Health Research
- UCLH Biomedical Research Centre
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Wilhelm Sander-Stiftung
- Else Kroner-Fresenius Stiftung
- European Union (European Regional Development Fund Investing in Your Future)
- German federal state North Rhine-Westphalia (NRW)
- Medical Faculty of the University
- MRC [G0902209] Funding Source: UKRI
- Medical Research Council [G0902209] Funding Source: researchfish
Viral and non-viral gene transfer technologies have been used to efficiently generate therapeutic T cells with desired cancer-specificity. Chimeric antigen receptors (CARs) redirect T cell specificity toward antibody-recognized antigens expressed on the surface of cancer cells, while T cell receptors (TCRs) extend the range of targets to include intracellular tumor antigens. CAR redirected T cells specific for the B cell differentiation antigen CD19 have shown dramatic efficacy in the treatment of B cell malignancies, while TCR-redirected T cells have shown benefits in patients suffering from solid cancer. In this review we will present strategies to optimize CAR and TCR function, and discuss the importance of target antigen selection to enhance tumor specificity, while reducing on-target and off-target toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据